Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Stopped Administrative hold pending non-safety related changes to the study design.

Conditions

• Multiple Myeloma
• Relapsed and/or Refractory Multiple Myeloma (RRMM)

Interventions

• DRUG: Mirdametinib
• DRUG: Sirolimus

Sponsor

National Cancer Institute (NCI)